All-trans retinoic acid and interferon-α for treatment of human renal cell carcinoma multicellular tumor spheroids

Urologia Internationalis

Volumn 73, Issue 1, 2004, Pages 47-53

  Rohde, Detlef ^a,b   Brkovic, Drasko ^a   D'Orville, Inga Hönig ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Academic Hospital Darmstadt   (Germany)

Author keywords

Cell culture; Interferon; Multicellular tumor cell spheroid; Renal cell carcinoma; Retinoic acid

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TUMOR SPHEROID;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; SPHEROIDS, CELLULAR; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 3242763129     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078804     Document Type: Article

References (52)

1. Pittman K, Selby P: The management of renal cell carcinoma. Crit Rev Oncol Hematol 1994;16:181-200.
2. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
3. Ritchie A: Interferon-α and survival in metastatic renal cell carcinoma: Early results of a randomized controlled trial. Lancet 1999;353:14-17.
4. Hancock B, Griffiths G, Ritchie A, Oliver RTD, Gore M, Mead G, Cook P, Parmar MKB: Updated results of the MRC randomized controlled trial of α-interferon vs. MPA in patients with metastatic renal carcinoma (abstract). Proc ASCO 2000, p 1336.
5. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer (Cochrane Review); in The Cochrane Library, 2001, Issue 1: Oxford: update software.
6. Wadler S, Schwartz EL: Antineoplastic activity of combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990;50:3473-3486.
7. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmüller HGW: Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 1996;156:168-121.
8. 2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial. Group Français d'Immunothérapie. J Clin Oncol 1998;16:2728-2732.
9. Igarashi T, Marumo K, Onishi T: Interferon-α and 5-fluorouracil therapy in patients with metastatic renal cell cancer: An open multicenter trial. The Japanese Study Group Against Renal Cancer. Urology 1999;53:53-59.
10. 2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-1278.
11. Négrier S, Caty A, Lesimple T, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Treatment of patients with metastatic renal cell carcinoma with a combination of subcutaneous interleukin-2 and interferon-α with or without fluorouracil. J Clin Oncol 2000;18:4009-4015.
12. Smit MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 1992;10:839-864.
13. 2a and 13-cis retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13:1950-1957.
14. 2a. Clin Cancer Res 1999;5:1671-1675.
15. Buer J, Probst M, Duesing S, Koditz H, Dallmann I, Ganser A, Atzpodien J: Clinical and in vitro response to 13-cis-retinoic acid in interferon-α- resistant renal cell carcinomas. Cancer Biother Radiopharm 1997;12:143-147.
16. Taguchi I, Hara I, Gohji K, Arakawa S, Kamidono S: Synergistic anti-tumor effect of 13-cRA and IFN-α/β in mouse renal cell carcinoma. Int J Oncol 1998;13:145-149.
17. Nanus DM, Geng Y, Shen R, Lai HK, Pfeffer SR, Pfeffer LM: Interaction of retinoic acid and interferon in renal cancer cell lines. J Interferon Cytokine Res 2000;20:787-794.
18. 2a in two patients with therapy-refractory advanced renal cell carcinoma. J Clin Oncol 1995;13:2679-2680.
19. 2a in the treatment of metastatic renal cell carcinoma. J Exp Clin Cancer Res 1998;17:227-229.
20. 2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. Cancer Invest 2000;18:417-421.
21. 2a with or without 13-cis retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972-2980.
22. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L: All-trans retinoic acid in acute promyelotic leukemias. II. In vitro studies: structure-function relationship. Blood 1990;76:1710-1717.
23. Bollag W, Holdener EE: Retinoids in prevention and therapy. Ann Oncol 1992;3:513-526.
24. Hamilton G: Multicellular spheroids as an in vitro tumor model. Cancer Lett 1998;131:29-34.
25. Kunz-Schughart LA, Kreuz M, Knuechel R: Multicellular spheroids: A three-dimensional in vitro culture system to study tumor biology. Int J Exp Pathol 1998;79:1-23.
26. Bukowski RM, Novick AC: Clinical practice guidelines: Renal cell carcinoma. Cleve Clin J Med 1997;64(suppl 1):1-44.
27. Dorr RT: Interferon-α in malignant and viral diseases. A review. Drugs 1993;45:177-211.
28. Haque SJ, Williams BR: Signal transduction in the interferon system. Semin Oncol 1998;25(suppl 1):14-22.
29. Pfahl M, Chytil F: Regulation of metabolism by retinoic acid and its nuclear receptors. Annu Rev Nutr 1996;16:257-283.
30. Lippmann SM, Davies PJ: Retinoids, neoplasia and differentiation therapy. Cancer Chemother Biol Response Modif 1997;17:349-362.
31. Sonneveld E, van der Saag PT: Metabolism of retinoic acid: Implications for development and cancer. Int J Vitam Nutr Res 1998;68:404-410.
32. Lotan R, Clifford JL: Nuclear receptors for retinoids: Mediators of retinoid effects on normal and malignant cells. Biomed Pharmacother 1991;45:145-156.
33. Napoli JL: Biochemical pathways of retinoid transport, metabolism and signal transduction. Clin Immunol Immunopathol 1996;80:52-62.
34. Lotan R, Dawson MI, Zou CC, Jong L, Lotan D, Zou CP: Enhanced efficacy of combinations of retinoic acid and retinoid x receptor-selective retinoids and α-interferon in inhibition of cervical carcinoma cell proliferation. Cancer Res 1995;55:232-236.
35. Kolla V, Lindner DJ, Xiao W, Borden EC, Kalvakolanu DV: Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Upregulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem 1996;217:10508-10514.
36. Gianni M, Terao M, Fortino I, LiCalzi M, Viggiano V, Barbui T, Rambaldi A, Garattini E: Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 1997;89:1001-1012.
37. Bhatti L, Sidell N: Transcriptional regulation by retinoic acid of interleukin-2α receptors in human B cells. Immunology 1994;81:273-279.
38. Fegan C, Bailey-Wood R, Coleman S, Philips SA, Neale L, Hoy T, Whittaker JA: All-trans retinoic acid enhances human LAK activity. Eur J Haematol 1995;54:95-100.
39. Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W: Synergistic effect of retinoids and interferon-α on tumor-induced angiogenesis: Antiangiogenic effect on HPV harboring tumor cell lines. Int J Cancer 1994;57:81-85.
40. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino AP, Nanus DM: Expression of retinoic acid receptor β in human renal cell carcinomas correlates with the sensitivity to the antiproliferative effects of 13-cisretinoic acid. Clin Cancer Res 1996;2:1077-1082.
41. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ: Multicenter phase II trial of interleukin-2, interferon-α, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998;16:1820-1825.
42. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J, Probst M, Anton P, Poliwoda H: Biochemotherapy of advanced metastatic renal-cell carcinoma: Results of the combination of interleukin-2, α-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 1995;13:174-177.
43. Oevermann K, Buer J, Hoffmann R, Franzke A, Schrader A, Patzelt T, Kirchner H, Atzpodien J: Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83:583-587.
44. Vaishampayan U, Flaherty L, Du W, Hussain M: Phase II evaluation of paclitaxel, α-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 2001;92:519-523.
45. Sacks PG, Oke V, Lotan R: Retinoic acid inhibition of a head and neck multicellular tumor spheroid model. Head Neck 1989;11:219-225.
46. Sacks PG, Oke V, Mehta K: Antiproliferative effects of free and liposome-encapsulated retinoic acid in a squamous carcinoma model: Monolayer cells and multicellular tumor spheroids. J Cancer Res Clin Oncol 1992;118:490-496.
47. 2a tretinoin in patients with metastatic renal cell carcinoma: A pilot study. Am J Health Syst Pharm 1997;54:190-192.
48. Escudier B, Ravaud A, Berton D, Chevreau C, Douillard JY, Dietrich PY: Phase II study of interferon-α and all-trans retinoic acid in metastatic renal cell carcinoma. J Immunother 1998;21:62-64.
49. Di Giovanna JJ: Retinoids for the future: Oncology. J Am Acad Dermatol 1992;27:34-37.
50. Muindi JR, Young CW, Warrell RP Jr: Clinical pharmacology of all-trans retinoic acid. Leukemia 1994;8:1807-1812.
51. Sonneveld E, van den Brink CE, van der Leede BM, Schulkes RK, Petkovich M, van der Burg B, van der Saag PT: Human retinoic acid (RA) 4-hydroxylase is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 1998;9:629-637.
52. Guo X, Nanus DM, Ruiz A, Rando RR, Bok D, Gudas J: Reduced levels of retinyl esters and vitamin A in human renal cancers. Cancer Res 2001;61:2774-2781.